
Loading, please wait...

Loading, please wait...

Fenestrated endovascular repair (FEVAR) provides an effective solution for complex aortic aneurysms. However, physicians often encounter complications like Type IIIc endoleaks. Effective Type IIIc endoleak management is critical because these leaks involve flow between the fenestration and the bridging stent. While some endoleaks resolve on their own, persistent ones require secondary interventions to prevent aneurysmal sac expansion and potential rupture.
Researchers recently described a percutaneous stent-and-plug rescue maneuver for refractory cases. The study followed five consecutive patients who failed prior angioplasty or re-stenting attempts. These endoleaks appeared at a mean of 2.47 months after the initial repair. Therefore, the surgical team developed a novel approach using a stent and a vascular plug to achieve a definitive seal in the fenestration-free space.
During the procedure, surgeons used bilateral femoral access under moderate sedation. They protected the target-vessel stent with a balloon while catheterizing the fenestration contralaterally. Subsequently, the team deployed a 5 × 16 mm iCast™ stent within the fenestration. They then positioned an Amplatzer vascular plug inside this new stent. Finally, the surgeons re-inflated the target-vessel balloon to crush the stent-plug complex, creating a mechanical seal.
The stent-and-plug technique achieved high technical success in the study cohort. Four out of five cases showed complete sealing immediately after the rescue maneuver. The remaining case required only one additional procedure to achieve a complete seal. Furthermore, the researchers observed no renal branch occlusion or dialysis-requiring renal injuries. Procedure-related mortality remained at zero, which highlights the safety of this percutaneous approach.
Follow-up data at a mean of 8.96 months showed no further aneurysm sac growth. This suggests that the maneuver provides a stable solution for patients who fail conventional secondary interventions. However, clinicians should maintain extended surveillance to confirm the long-term durability of the seal. This technique offers a feasible and safe option for managing persistent Type IIIc endoleaks when traditional methods fall short.
A Type IIIc endoleak refers to blood flow occurring through the space between a graft fenestration and the bridging stent that connects to a target vessel.
Clinicians should consider this technique for persistent Type IIIc endoleaks that fail to respond to standard angioplasty or traditional re-stenting attempts and are associated with potential sac expansion.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Refer to the latest local and national guidelines for clinical practice.
References
Alsarayreh M et al. A New Technique Using a Stent and a Plug for the Management of Persistent Type IIIc Endoleak Following Fenestrated Endovascular Aortic Repair (FEVAR). Vasc Endovascular Surg. 2026 Feb 19. doi: 10.1177/15385744261424745. PMID: 41711099.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Researchers describe a new stent-and-plug rescue maneuver for persistent Type IIIc endoleaks following FEVAR, showing promising results in refractory cases....
8 months ago

Explore vital recurrent stroke predictors in lacunar stroke patients managed with intensive blood pressure lowering. This analysis examines trial findings from SPS3 to uncover residual vascular risks, metabolic factors, and targeted secondary prevention strategies for high-risk neurological patients.
Today

Odisha has established India's first state-level clinical protocol specifically tailored for pregnant women with sickle cell disease. Developed with NHM and UNICEF, the framework provides structured antenatal screening, crisis mitigation, standardized referral pathways, and specialized interdisciplinary care.
Today

The Directorate General of Health Services directs Indian states to halt the hazardous reuse and reprocessing of single-use medical devices. Discover regulatory implications under the Drugs and Cosmetics Act, critical infection risks, legal liabilities, and operational changes required across clinical specialties.
Today

Mitochondria-targeted nanoparticles self-assembled from EGCG and L-glutamic acid effectively restore mitochondrial homeostasis, suppress synovial inflammation, and attenuate chondrocyte senescence in osteoarthritis, offering a promising disease-modifying nanotherapy.
Today

India is advancing preventive healthcare by integrating genomics, artificial intelligence, and quantum technologies. With the SANGAM programme sequencing one million Indian genomes, clinicians can unlock personalized therapies, detect cardiometabolic risks early, and curb the burden of diabetes and heart disease.
Today